Strides Pharma Science

    STAR
    Pharma
    ₹958.10
    Price as of 18 Nov 2026, 9:58 pm IST

    Market cap ₹8,831 Cr

    P/E
    14.32
    Day range
    ₹956.70 – ₹990.50
    52-week range
    ₹768.65 – ₹1,260.90
    Volume
    2.81 L
    Open
    ₹983.00
    Prev close
    ₹982.10

    Latest results · Q2 FY27(consolidated)Revenue ₹1,430 Cr+17.1%Profit ₹134 Cr+2.0%Margin 9.4%YoY vs the same quarter last year

    1 red flag to read up on

    • high

      High promoter pledge

      33.79% of promoter shares pledged · 30 Sept 2026

    From NSE and BSE filings. A flag is a reason to read the filing, not a rating.

    Research profile

    Composite 64 / 100

    Factor percentiles

    Value75
    Quality60
    Momentum46
    Low volatility75

    Derived metrics

    Earn. yield
    7.0%
    Graham no.
    ₹713.73
    vs Graham
    -25.5%
    ROE ÷ P/B
    7.7%
    12-1 mom.
    +12.5%
    Return / vol
    0.08
    Magic Formula
    #104
    Piotroski
    5/6
    FCF yield
    3.1%

    Percentiles rank this stock against the other tracked stocks and change as they do. Scans describe where figures sit today. Hover a label for its definition. Not investment advice.

    Peer comparison

    All 68 in Pharma
    Largest Pharma companies tracked, with sector medians
    CompanyM-capP/EP/BROEROCEOPMD/ESales YoY
    Sun PharmaSUNPHARMA₹4.49 L Cr40.955.0314.8%21.0%29.0%0.04+11.9%
    Divi's LaboratoriesDIVISLAB₹2.93 L Cr87.1916.8816.2%22.0%43.0%0.00+35.4%
    Torrent PharmaTORNTPHARM₹1.75 L Cr77.889.6726.8%15.0%33.0%0.77+50.8%
    Apollo HospitalsAPOLLOHOSP₹1.27 L Cr56.4011.5522.6%17.0%16.0%0.77+23.0%
    Laurus LabsLAURUSLABS₹1.25 L Cr93.7219.8218.2%18.0%34.0%0.43+33.5%
    Zydus LifesciencesZYDUSLIFE₹1.20 L Cr28.724.3220.1%21.0%24.0%0.50+29.2%
    Dr. Reddy's LabsDRREDDY₹1.17 L Cr41.632.9711.6%13.0%20.0%0.19-1.5%
    Strides Pharma ScienceSTAR₹8,831 Cr14.322.6520.3%18.0%18.0%0.56+17.1%
    Sector median₹24,603 Cr43.685.4615.1%17.0%24.0%0.17+22.7%

    Sector as classified in the tracked universe; medians use every tracked Pharma company, and P/E only profitable ones. Tinted figures beat the median.

    Key metrics

    P/E (TTM)
    15.7
    Price / Book
    2.58
    ROE (FY26)
    20.3%
    ROCE (latest year)
    18%
    Dividend yield
    0.51%

    Moving averages (NSE)

    20-day
    ₹1,023.21
    Price below
    50-day
    ₹1,094.01
    Price below
    200-day
    ₹1,025.99
    Price below

    Charts & trends

    From company filings. Amounts in ₹ crore.

    Revenue 3Y CAGR
    +9.6%
    Revenue YoY (Sep 2026)
    +17.1%
    Profit YoY (Sep 2026)
    +1.5%
    Operating margin
    18.0%
    Net margin
    9.4%

    Revenue, profit & margin - quarterly

    ₹ crore; a loss shows red. Operating margin below, same periods.

    0 Cr1K Cr2K Cr3K Cr4K Cr
    • Revenue
    • Net profit

    Operating margin

    Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Sep 20260%10%20%

    Who owns the company

    % of equity by quarter, latest Sept 2026

    Dec '24Mar '25Jun '25Sept '25Dec '25Mar '26Jun '26Sept '260%25%50%75%100%
    • Promoter
    • FII
    • Public
    • DII
    • Government

    Cash flows

    Where cash came from and went, by fiscal year (₹ crore)

    Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026-2K Cr-1K Cr0 Cr1K Cr2K Cr
    • Operating
    • Investing
    • Financing
    • Free cash flow

    Return on equity

    Net profit over shareholders' equity, by fiscal year

    FY17FY18FY19FY20FY21FY22FY23FY24FY25FY26-50%0%50%100%150%200%15% screen

    Equity vs debt

    Shareholders' equity against borrowings (₹ crore); the ratio below, same years.

    0 Cr1K Cr2K Cr3K Cr4K Cr
    • Equity
    • Debt

    Debt to equity

    Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Sep 20260x1x2x

    Dividends per share

    ₹ by fiscal year of the ex-date; the latest year runs to date.

    FY18FY19FY20FY21FY22FY23FY24FY25FY26FY27₹0₹5₹10₹15

    Financial statements

    ₹ Crore
    Quarterly results, oldest period first, figures in rupees crore
    Line itemDec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
    Sales1,0061,0441,0541,1671,1541,1901,1201,2211,1951,3231,2651,430
    Expenses8768748669839439739029909591,0841,0371,179
    Operating Profit129169188184210218218231236240228251
    OPM %13%16%18%16%18%18%19%19%20%18%18%18%
    Other Income60-273,299254-120181043683
    Interest707173745250474643424147
    Depreciation494847484849495051535657
    Profit before tax70233,36986114106122153245148200150
    Tax %23%55%1%16%21%20%13%14%15%13%17%11%
    Net Profit54103,350729086106132208129165134
    EPS in Rs₹5.40₹1.98₹364.69₹7.81₹9.54₹8.91₹10.80₹13.84₹21.93₹13.77₹17.02₹14.20

    From company filings, updated 18 Nov 2026. Consolidated figures where the company reports them. Information only, not investment advice.

    Working-capital cycle

    Debtor Days97

    -25 days since Mar 2021

    Inventory Days305

    -24 days since Mar 2021

    Days Payable244

    -79 days since Mar 2021

    Cash Conversion Cycle157

    +29 days since Mar 2021

    Working Capital Days38

    +60 days since Mar 2021

    Strengths, risks & growth

    Strides Pharma Science Ltd is in the business of development and manufacturing of pharmaceutical products. [1] The company's pharmaceutical products are sold in over 100 countries. [2] The company has always followed an inorganic growth strategy over the years that resulted in foray into new markets, addition of new business segments, therapy segments and manufacturing infrastructure. [3]

    Strengths

    • Company has delivered good profit growth of 20.1% CAGR over last 5 years
    • Company has a good return on equity (ROE) track record: 3 Years ROE 57.0%

    Risks

    • Stock is trading at 2.65 times its book value
    • The company has delivered a poor sales growth of 7.94% over past five years.
    • Promoter holding is low: 29.0%
    • Promoters have pledged 33.8% of their holding.

    Compounded Sales Growth

    10 Years
    +5%
    5 Years
    +8%
    3 Years
    +10%
    TTM
    +11%

    Compounded Profit Growth

    10 Years
    +16%
    5 Years
    +20%
    3 Years
    +71%
    TTM
    +33%

    Stock Price CAGR

    10 Years
    +7%
    5 Years
    +33%
    3 Years
    +63%
    1 Year
    +4%

    Return on Equity

    10 Years
    +22%
    5 Years
    +31%
    3 Years
    +57%
    Last Year
    +20%

    Strengths and risks are a machine-generated checklist, not advice; growth is compounded annually over each period.

    Shareholding pattern

    Percentage of shares held by each category at each quarter end
    HolderDec 2025Mar 2026Jun 2026Sept 2026Change
    Promoter27.86%27.91%27.91%29.00%+1.09 pp
    FII29.52%28.68%28.40%27.98%-0.42 pp
    DII13.02%14.44%15.42%15.51%+0.09 pp
    Government0.01%0.01%0.01%0.01%0.00 pp
    Public29.59%28.96%28.28%27.52%-0.76 pp

    Filed with NSE for Sept 2026: promoters 29.00%, public 71.00%

    Analysts & fund holdings

    100%
    100% recommend buy
    2 analysts cover the stock
    Valuation vs Pharmaceuticals
    P/E14.3 vs 45.1
    Sector P/B6.03
    Beta0.60

    Who holds the shares, quarter by quarter

    Mutual funds 10.31% (+1.58 pp)
    Jun 25
    Sept 25
    Dec 25
    Mar 26
    Jun 26
    Sept 26
    • Promoters29.0%
    • Foreign institutions28.0%
    • Mutual funds10.3%
    • Insurance3.5%
    • Other domestic institutions1.6%
    • Retail12.7%
    • Others14.8%
    Mutual funds holding the most
    Fund% of company% of fund3-month change
    Quant Small Cap Fund4.64%1.24%+0.15 pp
    Bandhan Small Cap Fund3.79%0.97%+0.38 pp
    Quant Multi Cap Fund1.75%2.11%+0.22 pp
    Axis Small Cap Fund0.87%0.27%+0.02 pp
    Quant Healthcare Fund0.40%8.79%+6.15 pp

    Scorecard

    Performance
    Avg
    Valuation
    High
    Growth
    Low
    Profitability
    High
    Entry point
    Good
    Red flags
    Low

    Analyst coverage, holdings and scorecard from market data; not a recommendation by Rajat Finance.

    Risk & trend

    From 292 daily sessions to 18 Nov 2026.

    Computed

    Risk

    Volatility (1Y)
    37.1%
    Downside volatility
    32.8%
    Worst 5% of days
    3.9%
    Average of that tail
    4.6%
    Max drawdown (1Y)
    22.4%
    Below its peak
    22.4%

    Against the market

    Beta vs Nifty 50
    0.50
    Correlation
    0.18
    Relative strength (3M)
    -6.8%
    ATR (14)
    4.0%

    Return

    Return 1M
    -8.3%
    Return 3M
    -2.9%
    Return 6M
    -16.8%
    Return 1Y
    +3.1%
    vs 200-day average
    -6.6%

    Momentum

    RSI (14)
    31.0
    MACD histogram
    -4.10
    Stochastic %K
    0.9
    ADX (14)
    31.6
    +DI / −DI
    12.1 / 29.4
    Money flow index
    20.9

    Participation

    Delivery (20d avg)
    49.6%
    vs its 60-day baseline
    +1.6 pts
    Volume vs 20-day
    -0.3σ
    Close vs day's VWAP
    -0.8%
    52-week position
    37 / 100

    These describe what this stock's price has already done. They are not forecasts, signals or recommendations, and a dash means the figure was withheld for want of enough history rather than being zero.

    Financial quality

    From consolidated statements to 30 Sept 2026.

    Computed

    Piotroski F-Score

    5 of 6 tested

    • Return on assets positive — passed
    • Operating cash flow positive — not testableno cash flow statement for this period
    • Return on assets improving — passed
    • Cash flow exceeds profit — not testableneeds cash flow and profit against assets
    • Debt to assets falling — passed
    • Current ratio improving — passed
    • No new equity issued — not testableno share count is collected, and financing cash flow mixes equity with debt
    • Operating margin improving — passed
    • Asset turnover improving — failed
    Free cash flow
    ₹285 Cr
    FCF yield
    3.1%
    Cash conversion
    1.22
    Accruals ratio
    -0.018
    Net debt
    ₹1,768 Cr
    Net debt / equity
    0.52
    EV / sales
    2.08
    Capex intensity
    8.6%
    Revenue CAGR
    13.0%
    Profit CAGR
    34.8%

    Computed from filed statements, not filed themselves. A dash means an input was absent, and the score counts only the criteria that could actually be tested.

    Corporate actions

    • dividend
      ₹5.00

      Dividend - Rs 5 Per Share

      31 Jul 2026
      ex-date
    • dividend
      ₹4.00

      Dividend - Rs 4 Per Share

      22 Jul 2025
      ex-date
    • other
      Not available — not reported in this filing

      Demerger

      6 Dec 2024
      ex-date
    • dividend
      ₹2.50

      Dividend - Rs 2.50 Per Share

      9 Sept 2024
      ex-date
    • dividend
      ₹1.50

      Dividend - Rs 1.50 Per Share

      4 Aug 2023
      ex-date
    • dividend
      ₹2.50

      Dividend - Rs 2.50 Per Share

      5 Aug 2021
      ex-date
    • dividend
      ₹2.00

      Annual General Meeting/Dividend - Rs 2 Per Share

      24 Jul 2020
      ex-date
    • dividend
      ₹12.00

      Interim Dividend - Rs 12 Per Share

      22 Aug 2019
      ex-date
    • dividend
      ₹3.00

      Annual General Meeting/Dividend - Rs 3 Per Share

      19 Jul 2019
      ex-date
    • dividend
      ₹2.00

      Annual General Meeting/Dividend Rs 2 Per Share

      12 Sept 2018
      ex-date
    • other
      Not available — not reported in this filing

      Scheme Of Arrangement

      6 Apr 2018
      ex-date
    • dividend
      ₹4.50

      Annual General Meeting/Dividend - Rs 4.50 Per Share

      7 Sept 2017
      ex-date
    • dividend
      ₹4.00

      Annual General Meeting/ Dividend - Rs 4/- Per Share

      21 Jul 2016
      ex-date
    • dividend
      ₹3.00

      Annual General Meeting/ Dividend - Rs 3/- Per Share

      22 Jul 2015
      ex-date
    • dividend
      ₹105.00

      Special Dividend Rs.105/- Per Share

      16 Oct 2014
      ex-date
    • dividend
      ₹5.00

      Annual General Meeting / Dividend - Rs 5/- Per Share

      1 Sept 2014
      ex-date
    • dividend
      ₹500.00

      Special Dividend - Rs 500/- Per Share

      19 Dec 2013
      ex-date
    • dividend
      ₹2.00

      Annual General Meeting And Dividend Rs.2/- Per Share

      30 May 2013
      ex-date
    • dividend
      ₹2.00

      Annual General Meeting And Dividend Rs.2/- Per Share

      14 May 2012
      ex-date
    • dividend
      ₹1.50

      Annual General Meeting And Dividend Rs.1.50 Per Share

      18 May 2011
      ex-date

    Company announcements

    Company Update
    Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

    Certificate in terms of regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended September 30, 2026

    Insider Trading / SAST
    Closure of Trading Window

    Closure of Trading Window for the quarter ended September 30, 2026

    Company Update
    Strides' Sustainability Report For FY26

    Strides' Sustainability Report for FY26

    Company Update
    Completion Of USFDA Inspection At The Company's Formulations Facility At Alathur

    Completion of USFDA Inspection at the Company's Formulation Facility at Alathur

    Company Update
    Announcement under Regulation 30 (LODR)-Press Release / Media Release

    Strides receives USFDA Establishment Inspection Report (EIR) for flagship facility in Bengaluru

    AGM/EGMPrice-sensitive
    Shareholder Meeting / Postal Ballot-Scrutinizer's Report

    Voting results along with Scrutinizers report for 35th AGM.

    AGM/EGMPrice-sensitive
    Shareholder Meeting / Postal Ballot-Outcome of AGM

    Proceedings of 35th Annual General Meeting of the Company

    Company Update
    Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

    Transcript of Earnings Call pertaining to Unaudited Financial Results of the Company for the quarter ended June 30, 2026.

    Company Update
    Announcement under Regulation 30 (LODR)-Newspaper Publication

    Newspaper advertisement - Unaudited Financial Results for the quarter ended June 30, 2026

    Company Update
    Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

    Audio Recording of Earnings Call dated July 31, 2026, pertaining to unaudited financial results for Q1 FY27

    Company Update
    Announcement under Regulation 30 (LODR)-Investor Presentation

    Earnings Presentation for the quarter ended June 30, 2026

    Company Update
    Announcement under Regulation 30 (LODR)-Press Release / Media Release

    Strides Delivers Steady Performance with Q1FY27; Revenue at Rs. 12,654m, Grew 13% YoY; Ex-US Markets Grew 17% YoY

    Result
    Outcome Of Board Meeting Of The Company Held On July 31, 2026

    Outcome of Board Meeting of the Company held on July 31, 2026

    Company Update
    Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    Earnings Call to discuss the Unaudited Financial Results of the Company for the quarter ended June 30, 2026

    Board MeetingPrice-sensitive
    Board Meeting Intimation for Considering And Approving The Unaudited Financial Results (Standalone And Consolidated) Of The Company For The Quarter Ended June 30, 2026, Amongst Other Matters.

    Strides Pharma Science Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 31/07/2026 ,inter alia, to consider and approve the unaudited financial ....

    Filed with BSE (scrip 532531); the last 45 days. Documents open at bseindia.com.

    Documents

    Credit ratings

    Documents open at BSE or the rating agency that issued them.

    Sourced from the company's NSE XBRL filing dated 30 Oct 2026 (unaudited). View the source filing. Figures are as filed and are not investment advice.

    FAQ

    Strides Pharma Science: common questions

    Answered from the figures on this page.

    Strides Pharma Science last traded at ₹958.10 (NSE, as of 18 Nov 2026). The last session moved it down 2.44%.

    Strides Pharma Science is valued at about ₹8,831 crore (NSE, as of 18 Nov 2026).

    Strides Pharma Science trades at a price-to-earnings ratio of 14.32 (NSE, as of 18 Nov 2026). The P/E compares the share price with earnings per share, so it is only comparable between companies in the same industry.

    Strides Pharma Science has traded between ₹768.65 and ₹1,260.90 over the past 52 weeks, to 18 Nov 2026. It is currently 38% of the way up that range.

    Strides Pharma Science (STAR) is classified under Pharma on this site's screener.